Ocular Therapeutix Inc.

13.51+0.0200+0.15%Vol 1.90M1Y Perf 48.09%
Jun 18th, 2021 16:00 DELAYED
BID13.52 ASK13.85
Open13.12 Previous Close13.49
Pre-Market- After-Market13.50
 - -  -0.01 -0.07%
Target Price
24.60 
Analyst Rating
Strong Buy 1.00
Potential %
82.09 
Finscreener Ranking
★★★★     53.82
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★+     45.03
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★★     54.49
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap1.03B 
Earnings Rating
Strong Sell
Price Range Ratio 52W %
37.12 
Earnings Date
6th Aug 2021

Today's Price Range

13.0113.72

52W Range

7.1424.30

5 Year PE Ratio Range

-2.40-3.50

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-6.51%
1 Month
-3.02%
3 Months
-34.64%
6 Months
-36.96%
1 Year
48.09%
3 Years
68.45%
5 Years
150.19%
10 Years
-

TickerPriceChg.Chg.%
OCUL13.510.02000.15
AAPL130.46-1.3300-1.01
GOOG2 511.35-16.0700-0.64
MSFT259.43-1.4700-0.56
XOM60.40-1.5900-2.56
WFC41.75-1.0400-2.43
JNJ161.98-3.2400-1.96
FB329.66-6.8500-2.04
GE12.78-0.2200-1.69
JPM147.92-3.8400-2.53
Financial StrengthValueIndustryS&P 500US Markets
8.10
8.30
0.36
0.68
-18.20
Leverage Ratio 4.50
ProfitabilityValueIndustryS&P 500US Markets
90.30
-561.00
-548.90
-2 323.40
-
RevenueValueIndustryS&P 500US Markets
22.14M
0.29
114.74
54.68
Earnings HistoryEstimateReportedSurprise %
Q01 2021-0.20-0.24-20.00
Q04 2020-0.18-0.23-27.78
Q03 2020-0.23-0.1726.09
Q02 2020-0.32-0.34-6.25
Q01 2020-0.40-0.41-2.50
Q04 2019-0.42-0.47-11.90
Q03 2019-0.46-0.452.17
Q02 2019-0.42-0.57-35.71
Earnings Per EndEstimateRevision %Trend
6/2021 QR-0.21-16.67Negative
9/2021 QR-0.19-26.67Negative
12/2021 FY-0.67-11.67Negative
12/2022 FY-0.38-153.33Negative
Next Report Date6th Aug 2021
Estimated EPS Next Report-0.21
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume1.90M
Shares Outstanding76.29M
Trades Count11.92K
Dollar Volume16.78M
Avg. Volume1.03M
Avg. Weekly Volume675.32K
Avg. Monthly Volume743.81K
Avg. Quarterly Volume1.09M

Ocular Therapeutix Inc. (NASDAQ: OCUL) stock closed at 13.51 per share at the end of the most recent trading day (a 0.15% change compared to the prior day closing price) with a volume of 1.93M shares and market capitalization of 1.03B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 161 people. Ocular Therapeutix Inc. CEO is Antony C. Mattessich.

The one-year performance of Ocular Therapeutix Inc. stock is 48.09%, while year-to-date (YTD) performance is -34.73%. OCUL stock has a five-year performance of 150.19%. Its 52-week range is between 7.14 and 24.3, which gives OCUL stock a 52-week price range ratio of 37.12%

Ocular Therapeutix Inc. currently has a PE ratio of -5.90, a price-to-book (PB) ratio of 13.22, a price-to-sale (PS) ratio of 49.80, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -81.74%, a ROC of -131.12% and a ROE of -363.55%. The company’s profit margin is -%, its EBITDA margin is -548.90%, and its revenue ttm is $22.14 Million , which makes it $0.29 revenue per share.

Of the last four earnings reports from Ocular Therapeutix Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.21 for the next earnings report. Ocular Therapeutix Inc.’s next earnings report date is 06th Aug 2021.

The consensus rating of Wall Street analysts for Ocular Therapeutix Inc. is Strong Buy (1), with a target price of $24.6, which is +82.09% compared to the current price. The earnings rating for Ocular Therapeutix Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Ocular Therapeutix Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Ocular Therapeutix Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 9.51, ATR14 : 0.77, CCI20 : -131.88, Chaikin Money Flow : 0.07, MACD : -0.47, Money Flow Index : 40.97, ROC : -6.31, RSI : 37.67, STOCH (14,3) : 24.58, STOCH RSI : 0.13, UO : 45.34, Williams %R : -75.42), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Ocular Therapeutix Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (100.00 %)
5 (83.33 %)
4 (80.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
1 (16.67 %)
1 (20.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.33
Strong Buy
1.40

Ocular Therapeutix Inc.

Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Ocular Therapeutix aims to offer medication to replace the existing eye-drop therapy regimen, with the aim of lasting weeks or months with a one-time product application.

CEO: Antony C. Mattessich

Telephone: +1 781 357-4000

Address: 24 Crosby Drive, Bedford 01730, MA, US

Number of employees: 161

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

0%100%

Bearish Bullish

53%47%

Bearish Bullish

48%52%

News

Stocktwits